Table 5.

CSF IgG analysis and leukocyte count after T cell therapy.

Participant code	Time of sample collection	CSF IgG Index (Reference range <0.70)	IgG (loc)a	IGGPROD (mg/L)b	Leukocyte count (× 106/L)
1	Baseline	0.69	1.6	7.8	1
	Month 6	0.61	−2.3	5.2	<1
	Year 2	0.93	12.2	18.5	2
	Year 3c	0.78	5.4	12.0	1
2	Baseline	0.90	20.9	32.8	2
	Month 6	0.88	19.1	31.3	4
	Year 2	0.96	22.9	33.6	3
	Year 3	Patient did not consent
3	Baseline	0.60	−8.5	9.5	<1
	Month 6	Patient did not consent
	Year 2	LP contraindicated owing to anti-coagulation
	Year 3
4	Baseline	0.89	17.6	28.6	1
	Month 6	1.04	25.8	35.2	8
	Year 2	1.32	29.6	36.8	<1
	Year 3	0.79	5.3	12.5	1
5	Baseline	0.48	−14.8	−2.5	<1
	Month 6	0.48	−13.1	−2.2	<1
	Year 2	0.47	−15.3	−3.1	<1
	Year 3	0.50	−10.7	−0.9	<1
6	Baseline	0.59	−5.5	5.7	<1
	Month 6	0.50	−15.0	−1.2	3
	Year 2	Blood-stained sampled	−11.7	−0.4	1
	Year 3	0.50
8	Baseline	0.93	17.1	25.9	8
	Month 6	1.08	25.1	33.7	2
	Year 2	Patient did not consent
	Year 3	Patient did not consent
9	Baseline	0.68	2.1	13.2	<1
	Month 6	0.63	−23.8	−8.5	<1
	Year 2	0.79	8.7	17.7	<1
	Year 3	Blood-stained sampled
12	Baseline	0.55	−9.2	3.3	2
	Month 6	0.57	−8.3	6.2	2
	Year 2	0.52	−12.6	0.6	1
	Year 3	Unsuccessful LP
13	Baseline	1.03	19.4	26.7	2
	Month 6	0.70	5.7	15.7	3
	Year 2	0.88	12.1	19.4	4
	Year 3e	0.68	1.7	9.8	1

^a intrathecal IgG production (IgG(loc)) was calculated by the formula of Reiber and Felgenhauer: (30) IgG(loc) (mg/L) = [(CSF IgG ÷ serum IgG) – [0.8 × (√((CSF albumin ÷ serum albumin)2 + 15))] + 1.8] × serum IgG.

^bintrathecal IgG production (IGGPROD) was calculated by the formula of now and colleagues: (31) CSF IgG-[(0.51 × CSF albumin × serum IgG)/serum albumin].

^cthis patient received ocrelizumab 3 months prior to the year 3 CSF examination.

^dthe results of this sample were disregarded because the CSF was contaminated with proteins and cells from the blood.

^ethis patient commenced ocrelizumab 2 months prior to the year 3 CSF examination.

LP, lumbar puncture.